Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7303132 | 0.88 | MAOB (0.43) | MAOBALDH1A1HSD17B10PKMMAPK1 | |
| SCHEMBL7302386 | 0.81 | MAOB (0.58) | MAOBACHEMAOA | |
| SCHEMBL7302120 | 0.81 | KDM4E (0.50) | ALDH1A1HSD17B10KDM4EMEN1MAPT | |
| SCHEMBL7295957 | 0.80 | MAOB (0.40) | MAOBALDH1A1HSD17B10PKMMAPK1 | |
| SCHEMBL7301258 | 0.79 | MAOB (0.48) | MAOBALDH1A1HSD17B10ACHEKDM4E | |
| SCHEMBL7434463 | 0.75 | MAOB (0.58) | MAOBACHEMAOA | |
| SCHEMBL7304086 | 0.74 | SLC26A3 (0.43) | MAOBALDH1A1HSD17B10ACHEKDM4E | |
| SCHEMBL7302076 | 0.73 | MAOB (0.61) | MAOBALDH1A1HSD17B10MAPK1ACHE | |
| SCHEMBL5617595 | 0.71 | MAOB (0.50) | MAOBALDH1A1HSD17B10PKMMAPK1 | |
| SCHEMBL7305804 | 0.69 | MAOB (0.44) | MAOBACHEMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| EP-0363796-B1 | HETEROCYCLICALLY SUBSTITUTED ALKOXYCOUMARINES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL AGENTS CONTAINING SAME | BASF Aktiengesellschaft (DE) | 1993-08-11 | — | — | EP | disclosed |
| US-5227392-A | Monoamine oxidase inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-13 | — | — | US | disclosed |
| US-5073563-A | Enzyme inhibitors, CNS | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-17 | — | — | US | disclosed |
| EP-0363796-A1 | Heterocyclically substituted alkoxycoumarines, method for their preparation and therapeutical agents containing same | BASF Aktiengesellschaft (DE) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885ALDH1A1 664/4885HSD17B10 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.